Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thrombotargets Corp.

This article was originally published in Start Up

Executive Summary

Company executives at Thrombotargets hit the ground running upon its 2005 founding in Barcelona, Spain. In two years, they have developed a pipeline of 11 hemostatics, anticoagulants, antiplatelets and fibrinolytics, all enabled by the company's proprietary high-throughput screening process, BioPlatformScreen. Thrombotargets is now preparing for clinical trials of its lead candidate, an antihemorrhagic human recombinant protein that has received FDA orphan drug status for two indications.

You may also be interested in...



ZymoGenetics Experiences a Biotech Disconnect

It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out it's not an easy sell, especially to Wall Street.

ZymoGenetics' Biotech Disconnect

It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out that it's not an easy sell, especially to Wall Street.

Start-Up Previews

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "The Drug Delivery Road Gets Tougher," features profiles of ActoGeniX, Atacama Labs, Glide Pharma and Mimetic Solutions. Plus these Start-Ups Across Health Care: Light Dimensions, Relyspa, Stentys and Thrombotargets.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel